BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32231733)

  • 1. The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells.
    Li Z; Yang C; Li X; Du X; Tao Y; Ren J; Fang F; Xie Y; Li M; Qian G; Xu L; Cao X; Wu Y; Lv H; Hu S; Lu J; Pan J
    J Cancer; 2020; 11(11):3274-3287. PubMed ID: 32231733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis.
    Czaplinski S; Hugle M; Stiehl V; Fulda S
    Oncotarget; 2016 Feb; 7(8):8700-11. PubMed ID: 26046302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
    Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
    Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A; Hugle M; Fulda S
    Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
    Grinshtein N; Datti A; Fujitani M; Uehling D; Prakesch M; Isaac M; Irwin MS; Wrana JL; Al-Awar R; Kaplan DR
    Cancer Res; 2011 Feb; 71(4):1385-95. PubMed ID: 21303981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth.
    Chilamakuri R; Rouse DC; Agarwal S
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
    Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
    Tao YF; Li ZH; Du WW; Xu LX; Ren JL; Li XL; Fang F; Xie Y; Li M; Qian GH; Li YH; Li YP; Li G; Wu Y; Feng X; Wang J; He WQ; Hu SY; Lu J; Pan J
    Oncol Rep; 2017 Mar; 37(3):1419-1429. PubMed ID: 28184925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
    Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.
    Oliveira JC; Pezuk JA; Brassesco MS; Morales AG; Queiroz RG; Scrideli CA; Tone LG
    Pediatr Blood Cancer; 2014 Jul; 61(7):1227-31. PubMed ID: 24519995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
    Choi M; Kim W; Cheon MG; Lee CW; Kim JE
    Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells.
    Chen Z; Chai Y; Zhao T; Li P; Zhao L; He F; Lang Y; Qin J; Ju H
    J Cell Physiol; 2019 May; 234(5):5904-5914. PubMed ID: 30488440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
    Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
    Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.